Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients
Abstract Background Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of CRS/HIPEC in patients with cirrhosis. The aim of this case series is to...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12957-018-1389-3 |
id |
doaj-18d01fc8d7d64affa9f1ad6a61b055c6 |
---|---|
record_format |
Article |
spelling |
doaj-18d01fc8d7d64affa9f1ad6a61b055c62020-11-25T01:17:02ZengBMCWorld Journal of Surgical Oncology1477-78192018-04-011611710.1186/s12957-018-1389-3Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patientsAnna Weiss0Erin P. Ward1Joel M. Baumgartner2Andrew M. Lowy3Kaitlyn J. Kelly4Department of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer CenterDepartment of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer CenterDepartment of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer CenterDepartment of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer CenterDepartment of Surgery, Division of Surgical Oncology, University of California, San Diego, Moores Cancer CenterAbstract Background Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of CRS/HIPEC in patients with cirrhosis. The aim of this case series is to report the outcomes of three patients with well-compensated cirrhosis who underwent CRS/HIPEC. Methods Patients were identified from a prospectively maintained peritoneal surface malignancy database. Patient, tumor, and operative-related details were recorded as short-term postoperative outcomes. Results were analyzed using descriptive statistics. Results All patients had well-compensated (Child-Pugh Class A) cirrhosis and Eastern Cooperative Oncology Group (ECOG) performance status of 0. One patient had preoperative evidence of portal hypertension. All safely underwent CRS/HIPEC with completeness of cytoreduction (CC) scores of 0. The postoperative morbidity profile was unique, but all complications were manageable and resulted in full recovery to preoperative baseline status. Conclusions Patient selection for CRS/HIPEC is critical for optimization of short- and long-term outcomes. This small series suggests that well-compensated cirrhosis should not be an absolute contraindication to CRS/HIPEC.http://link.springer.com/article/10.1186/s12957-018-1389-3Cytoreductive surgeryCytoreductionHIPECCirrhosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Anna Weiss Erin P. Ward Joel M. Baumgartner Andrew M. Lowy Kaitlyn J. Kelly |
spellingShingle |
Anna Weiss Erin P. Ward Joel M. Baumgartner Andrew M. Lowy Kaitlyn J. Kelly Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients World Journal of Surgical Oncology Cytoreductive surgery Cytoreduction HIPEC Cirrhosis |
author_facet |
Anna Weiss Erin P. Ward Joel M. Baumgartner Andrew M. Lowy Kaitlyn J. Kelly |
author_sort |
Anna Weiss |
title |
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
title_short |
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
title_full |
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
title_fullStr |
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
title_full_unstemmed |
Cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
title_sort |
cirrhosis is not a contraindication to cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in highly selected patients |
publisher |
BMC |
series |
World Journal of Surgical Oncology |
issn |
1477-7819 |
publishDate |
2018-04-01 |
description |
Abstract Background Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of CRS/HIPEC in patients with cirrhosis. The aim of this case series is to report the outcomes of three patients with well-compensated cirrhosis who underwent CRS/HIPEC. Methods Patients were identified from a prospectively maintained peritoneal surface malignancy database. Patient, tumor, and operative-related details were recorded as short-term postoperative outcomes. Results were analyzed using descriptive statistics. Results All patients had well-compensated (Child-Pugh Class A) cirrhosis and Eastern Cooperative Oncology Group (ECOG) performance status of 0. One patient had preoperative evidence of portal hypertension. All safely underwent CRS/HIPEC with completeness of cytoreduction (CC) scores of 0. The postoperative morbidity profile was unique, but all complications were manageable and resulted in full recovery to preoperative baseline status. Conclusions Patient selection for CRS/HIPEC is critical for optimization of short- and long-term outcomes. This small series suggests that well-compensated cirrhosis should not be an absolute contraindication to CRS/HIPEC. |
topic |
Cytoreductive surgery Cytoreduction HIPEC Cirrhosis |
url |
http://link.springer.com/article/10.1186/s12957-018-1389-3 |
work_keys_str_mv |
AT annaweiss cirrhosisisnotacontraindicationtocytoreductivesurgeryandhyperthermicintraperitonealchemotherapyinhighlyselectedpatients AT erinpward cirrhosisisnotacontraindicationtocytoreductivesurgeryandhyperthermicintraperitonealchemotherapyinhighlyselectedpatients AT joelmbaumgartner cirrhosisisnotacontraindicationtocytoreductivesurgeryandhyperthermicintraperitonealchemotherapyinhighlyselectedpatients AT andrewmlowy cirrhosisisnotacontraindicationtocytoreductivesurgeryandhyperthermicintraperitonealchemotherapyinhighlyselectedpatients AT kaitlynjkelly cirrhosisisnotacontraindicationtocytoreductivesurgeryandhyperthermicintraperitonealchemotherapyinhighlyselectedpatients |
_version_ |
1725148719165210624 |